Antidepressant-emergent mood switch in Korean adolescents with mood disorder

Clinical Neuropharmacology

Volumn 37, Issue 6, 2014, Pages 177-185

  Park, Kee Jeong ^a   Shon, Seunghyun ^a   Lee, Hyun Jeong ^a   Joo, Yeonho ^a   Youngstrom, Eric A ^b   Kim, Hyo Won ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Adolescent; Antidepressant; Clinical characteristics; Depression; Mood switch

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CHLORPROMAZINE; ESCITALOPRAM; FLUOXETINE; LAMOTRIGINE; MIRTAZAPINE; MOOD STABILIZER; NEUROLEPTIC AGENT; PAROXETINE; SERTRALINE; TRAZODONE; VENLAFAXINE; TRIAZINE DERIVATIVE;

ADOLESCENT; ANTIDEPRESSANT EMERGENT MOOD SWITCH; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; COMORBIDITY; CONDUCT DISORDER; CONFERENCE PAPER; DEPRESSION; EATING DISORDER; FAMILY HISTORY; FEMALE; FOLLOW UP; HUMAN; HYPOMANIA; KOREAN (PEOPLE); MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MENTAL DISEASE; MOOD DISORDER; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHIATRIST; RETROSPECTIVE STUDY; SEX RATIO; SOCIAL STATUS; SUICIDE ATTEMPT; CHEMICALLY INDUCED; CHILD; COMPLICATION; CROSS-SECTIONAL STUDY; DEPRESSIVE DISORDER; MOOD DISORDERS; RISK FACTOR; SOUTH KOREA;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; CHILD; CROSS-SECTIONAL STUDIES; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; MOOD DISORDERS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK FACTORS; TRIAZINES;

EID: 84927690675     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0000000000000055     Document Type: Conference Paper

References (58)

1. Birmaher B, Ryan ND, Williamson DE, et al. Childhood and adolescent depression: a review of the past 10 years part I. J Am Acad Child Adolesc Psychiatry 1996;35(11):1427-1439.
2. Cho SC, Go BJ, Kim BN, et al. The 2005 Seoul Child and Adolescent Mental Health Survey. Seoul Child and Adolescent Mental Health Center: Seoul, South Korea; 2006.
3. Korea Centers for Disease Control and Prevention. Korean Youth Risk Behavior Web-Based Survey: Survey Summaries. Seoul, South Korea: Korea Centers for Disease Control and Prevention; 2012.
4. Brent DA, Weersing VR. Depressive disorders. In: Martin A, Volkmar FR, ed. Lewis's Child and Adolescent Psychiatry. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007.
5. Kovacs M. Presentation and course of major depressive disorder during childhood and later years of the life span. J Am Acad Child Adolesc Psychiatry 1996;35(6):705-715.
6. Weissman MM, Wolk S, Goldstein RB, et al. Depressed adolescents grown up. JAMA 1999;281(18):1707-1713.
7. Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007;297(15):1683-1696.
8. Shirazi E, Alaghband-Rad J. An open trial of citalopram in children and adolescents with depression. J Child Adolesc Psychopharmacol 2005;15(2):233-239.
9. Martin A, Young C, Leckman JF, et al. Age effects on antidepressant-induced manic conversion. Arch Pediatr Adolesc Med 2004;158(8):773-780.
10. Gibbons RD, Brown CH, Hur K, et al. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 2007;164(9):1356-1363.
11. Katz LY, Kozyrskyj AL, Prior HJ, et al. Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults. CMAJ 2008;178(8):1005-1011.
12. Chun BJ, Dunner DL. A review of antidepressant-induced hypomania in major depression: suggestions for DSM-V. Bipolar Disord 2004;6(1):32-42.
13. Goldberg JF, Truman CJ. Antidepressant-induced mania: an overview of current controversies. Bipolar Disord 2003;5(6):407-420.
14. Wilens TE, Biederman J, Kwon A, et al. A systematic chart review of the nature of psychiatric adverse events in children and adolescents treated with selective serotonin reuptake inhibitors. J Child Adolesc Psychopharmacol 2003;13(2):143-152.
15. Benazzi F. Antidepressant-associated hypomania in outpatient depression: a 203-case study in private practice. J Affect Disord 1997;46(1):73-77.
16. Strober M, Carlson G. Bipolar illness in adolescents with major depression: clinical, genetic, and psychopharmacologic predictors in a three-to four-year prospective follow-up investigation. Arch Gen Psychiatry 1982;39(5):549-555.
17. Bond DJ, Noronha MM, Kauer-Sant'anna M, et al. Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: a systematic review and meta-analysis. J Clin Psychiatry 2008;69(10):1589-1601.
18. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003;60 (4):392-400.
19. Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003;64(9):1013-1024.
20. Shon SH, Joo YH, Lee JS, et al. Lamotrigine treatment of adolescents with unipolar and bipolar depression: a retrospective chart review. J Child Adolesc Psychopharmacol 2014;24(5):285-287.
21. Chang K, Saxena K, Howe M. An open-label study of lamotrigine adjunct or monotherapy for the treatment of adolescents with bipolar depression. J Am Acad Child Adolesc Psychiatry 2006;45(3):298-304.
22. Biederman J, Joshi G, Mick E, et al. A prospective open-label trial of lamotrigine monotherapy in children and adolescents with bipolar disorder. CNS Neurosci Ther 2010;16(2):91-102.
23. McElroy SL, Zarate CA, Cookson J, et al. A 52-week, open-label continuation study of lamotrigine in the treatment of bipolar depression. J Clin Psychiatry 2004;65(2):204-210.
24. Shon SH, Joo YH, Park JH, et al. Comparison of clinical characteristics of bipolar and depressive disorders in Korean clinical sample of youth: a retrospective chart review. Eur Child Adolesc Psychiatry 2014;23(5):307-316.
25. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. Washington, DC: American Psychiatric Association; 2000.
26. Park KS, Yoon JR, Park HJ, et al. Korean Educational Development Institute-Weschler Intelligence Scale for Children (KEDI-WISC). Korean Educational Development Institutes: Seoul, South Korea; 2002.
27. Andreasen NC, Pressler M, Nopoulos P, et al. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry 2010;67(3):255-262.
28. Axelson D, Birmaher B, Strober M, et al. Phenomenology of children and adolescents with bipolar spectrum disorders. Arch Gen Psychiatry 2006;63(10):1139-1148.
29. Findling RL, Reed MD, Myers C, et al. Paroxetine pharmacokinetics in depressed children and adolescents. J Am Acad Child Adolesc Psychiatry 1999;38(8):952-959.
30. Wada K, Sasaki T, Jitsuiki H, et al. Manic/hypomanic switch during acute antidepressant treatment for unipolar depression. J Clin Psychopharmacol 2006;26(5):512-515.
31. Baumer FM, Howe M, Gallelli K, et al. A pilot study of antidepressant-induced mania in pediatric bipolar disorder: characteristics, risk factors, and the serotonin transporter gene. Biol Psychiatry 2006;60(9):1005-1012.
32. Faedda GL, Baldessarini RJ, Glovinsky IP, et al. Treatment-emergent mania in pediatric bipolar disorder: a retrospective case review. J Affect Disord 2004;82(1):149-158.
33. Benvenuti A, Rucci P, Miniati M, et al. Treatment-emergent mania/hypomania in unipolar patients. Bipolar Disord 2008;10(6):726-732.
34. Barak Y, Kimhi R, Weizman R. Is selectivity for serotonin uptake associated with a reduced emergence of manic episodes in depressed patients?. Int Clin Psychopharmacol 2000;15(1):53-56.
35. Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry 1994;164(4):549-550.
36. Manwani SG, Pardo TB, Albanese MJ, et al. Substance use disorder and other predictors of antidepressant-induced mania: a retrospective chart review. J Clin Psychiatry 2006;67(9):1341-1345.
37. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 2013;15(1):1-44.
38. Amit BH, Weizman A. Antidepressant treatment for acute bipolar depression: an update. Depress Res Treat 2012;2012: 684725.
39. Henry C, Sorbara F, Lacoste J, et al. Antidepressant-induced mania in bipolar patients: identification of risk factors. J Clin Psychiatry 2001;62(4):249-255.
40. Merikangas KR, He JP, Burstein M, et al. Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication-Adolescent Supplement (NCS-A). J Am Acad Child Adolesc Psychiatry 2010;49(10):980-989.
41. Goldberg JF, Whiteside JE. The association between substance abuse and antidepressant-induced mania in bipolar disorder: a preliminary study. J Clin Psychiatry 2002;63(9):791-795.
42. Truman CJ, Goldberg JF, Ghaemi SN, et al. Self-reported history of manic/hypomanic switch associated with antidepressant use: data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). J Clin Psychiatry 2007;68(10):1472-1479.
43. Jerome L. Hypomania with fluoxetine. J Am Acad Child Adolesc Psychiatry 1991;30(5):850-851.
44. Venkataraman S, Naylor MW, King CA. Mania associated with fluoxetine treatment in adolescents. J Am Acad Child Adolesc Psychiatry 1992;31(2):276-281.
45. van der Loos ML, Mulder PG, Hartong EG, et al. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70(2):223-231.
46. Raskin S, Teitelbaum A, Zislin J, et al. Adjunctive lamotrigine as a possible mania inducer in bipolar patients. Am J Psychiatry 2006;163(1):159-160.
47. Margolese HC, Beauclair L, Szkrumelak N, et al. Hypomania induced by adjunctive lamotrigine. Am J Psychiatry 2003;160(1):183-184.
48. Subodh NB, Jayarajan D, Chand PK, et al. Lamotrigine-induced manic switch: a report of 2 cases. Prim Care Companion CNS Disord 2011;13(1). doi: 10.4088/PCC.10101034.
49. Barbee JG, Jamhour NJ. Lamotrigine as an augmentation agent in treatment-resistant depression. J Clin Psychiatry 2002;63(8):737-741.
50. Barbosa L, Berk M, Vorster M. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry 2003;64(4):403-407.
51. Eroʇlu MZ, Karakup G, Tamam L. Manic switch after adjuvant lamotrigine treatment. JMOOD 2012;2(3):129-132.
52. Desarkar P, Sinha VK. Lamotrigine-induced severe manic switch. Aus N Z J Psychiatry 2006;40(8):718.
53. Joseph MF, Youngstrom EA, Soares JC. Antidepressant-coincident mania in children and adolescents treated with selective serotonin reuptake inhibitors. Future Neurol 2009;4(1):87-102.
54. Marangell LB, Bauer MS, Dennehy EB, et al. Prospective predictors of suicide and suicide attempts in 1,556 patients with bipolar disorders followed for up to 2 years. Bipolar Disord 2006;8(5 Pt 2):566-575.
55. Goldstein TR, Ha W, Axelson DA, et al. Predictors of prospectively examined suicide attempts among youth with bipolar disorder. Arch Gen Psychiatry 2012;69(11):1113-1122.
56. Esposito-Smythers C, Goldstein T, Birmaher B, et al. Clinical and psychosocial correlates of non-suicidal self-injury within a sample of children and adolescents with bipolar disorder. J Affect Disord 2010;125(1-3):89-97.
57. Garb HN. Studying the Clinician: Judgment Research and Psychological Assessment. Washington, DC: American Psychological Association; 1998.
58. Berkson J. Limitations of the application of fourfold table analysis to hospital data. Biometrics 1946;2(3):47-53.